Covalently Linked Alpha-Galactosidase for Stable Fabry Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Fabry disease treatments using mammalian-cell derived recombinant α-galactosidase-A are limited in efficacy, fail to halt disease progression, and can induce immunogenic responses, necessitating improved enzyme stability and activity under physiological and lysosomal conditions.
Innovation Solution
Development of multimeric protein structures comprising covalently linked α-galactosidase monomers via a linking moiety, enhancing enzyme activity and stability in human plasma and lysosomal environments, and increasing circulating half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mammalian-cell derived recombinant α-galactosidase-A is used for Fabry disease treatment, then enzyme replacement therapy can be provided, but the treatment has limited efficacy, fails to halt disease progression, and induces immunogenic responses
Solution Approach 1:
The patent applies parameter changes by modifying the enzyme structure through cross-linking to alter its physical and chemical properties. The cross-linked α-galactosidase exhibits enhanced stability, extended plasma half-life, and reduced immunogenicity compared to the native enzyme, directly addressing the contradiction between treatment efficacy and immunogenic response
Solution Approach 2:
The patent creates a composite enzyme structure by cross-linking multiple α-galactosidase monomers together. This composite multimeric structure combines the catalytic activity of individual enzymes while providing enhanced stability and reduced immunogenicity through the cross-linked network, resolving the contradiction between therapeutic benefit and harmful immune response
2Productivity
If current recombinant α-galactosidase treatments are administered, then some enzyme function is restored, but the treatments only decelerate disease progress and cannot stop it
Solution Approach 1:
The patent implements partial or excessive action by creating cross-linked enzyme multimers that provide more than sufficient enzyme activity. The cross-linked structures exhibit enhanced catalytic efficiency and prolonged circulation time, delivering excessive enzyme function that can fully halt disease progression rather than merely decelerating it
3Object-affected harmful factors
If enzyme replacement therapy is discontinued due to immunogenicity, then patient safety is compromised, but continuing treatment exposes patients to ongoing immune responses
Solution Approach 1:
The patent converts the harmful immunogenicity of the native enzyme into a beneficial property through cross-linking modification. The cross-linked structure reduces immune recognition and response, transforming the enzyme from an immunogenic threat into a safe, continuous therapy that can be administered long-term without compromising patient safety or treatment continuity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimeric protein structures demonstrate enhanced enzyme activity and stability, maintaining activity levels and extending half-life, effectively addressing the limitations of existing treatments.
Implementation Method 1
Endogenous and recombinant α-GALs catalyze the hydrolysis of terminal galactosylated glycolipids in the lysosomes of cells
Data Source
AI summary
Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.